BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 33585986)

  • 1. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer.
    Pölcher M; Braun M; Tischitz M; Hamann M; Szeterlak N; Kriegmair A; Brambs C; Becker C; Stoetzer O
    Arch Gynecol Obstet; 2021 Sep; 304(3):783-790. PubMed ID: 33585986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
    Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
    Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
    Robertson S; Rönnlund C; de Boniface J; Hartman J
    Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer.
    Chen X; Sun L; Mao Y; Zhu S; Wu J; Huang O; Li Y; Chen W; Wang J; Yuan Y; Fei X; Jin X; Shen K
    BMC Cancer; 2013 Aug; 13():390. PubMed ID: 23957561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surrogate Molecular Classification of Invasive Breast Carcinoma: A Comparison Between Core Needle Biopsy and Surgical Excision, With and Without Neoadjuvant Therapy.
    Ambrosini-Spaltro A; Zunarelli E; Bettelli S; Lupi M; Bernardelli G; Milani M; Ficarra G
    Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):551-557. PubMed ID: 31335485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance of immunohistochemistry between core needle biopsy and surgical resection of breast cancer.
    Kombak FE; Şahin H; Mollamemişoğlu H; Önem İ; Kaya H; Buğdaycı O; Arıbal E
    Turk J Med Sci; 2017 Dec; 47(6):1791-1796. PubMed ID: 29306240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.
    Chen X; Zhu S; Fei X; Garfield DH; Wu J; Huang O; Li Y; Zhu L; He J; Chen W; Jin X; Shen K
    BMC Cancer; 2015 Oct; 15():822. PubMed ID: 26514283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens.
    Tendl-Schulz KA; Rössler F; Wimmer P; Heber UM; Mittlböck M; Kozakowski N; Pinker K; Bartsch R; Dubsky P; Fitzal F; Filipits M; Eckel FC; Langthaler EM; Steger G; Gnant M; Singer CF; Helbich TH; Bago-Horvath Z
    Virchows Arch; 2020 Oct; 477(4):545-555. PubMed ID: 32383007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer.
    Ricci MD; Calvano Filho CM; Oliveira Filho HR; Filassi JR; Pinotti JA; Baracat EC
    Rev Assoc Med Bras (1992); 2012; 58(5):532-6. PubMed ID: 23090222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients.
    Qi P; Yang Y; Bai QM; Xue T; Ren M; Yao QL; Yang WT; Zhou XY
    Breast Cancer Res Treat; 2021 Apr; 186(2):327-342. PubMed ID: 33439420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Core needle biopsy as an alternative to whole section in IHC4 score assessment for breast cancer prognostication.
    Liu M; Tang SX; Tsang JYS; Shi YJ; Ni YB; Law BKB; Tse GMK
    J Clin Pathol; 2018 Dec; 71(12):1084-1089. PubMed ID: 30228212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
    Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
    Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers.
    Shanmugalingam A; Hitos K; Hegde S; Al-Mashat A; Pathmanathan N; Edirimmane S; Hughes TM; Ngui NK
    Breast Cancer Res Treat; 2022 May; 193(1):151-159. PubMed ID: 35229238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
    Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
    J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
    Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
    Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience.
    Slostad JA; Yun NK; Schad AE; Warrior S; Fogg LF; Rao R
    Cancer Med; 2022 Dec; 11(24):4954-4965. PubMed ID: 35733293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens.
    Janeva S; Parris TZ; Nasic S; De Lara S; Larsson K; Audisio RA; Olofsson Bagge R; Kovács A
    BMC Cancer; 2021 Apr; 21(1):439. PubMed ID: 33879115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
    Asogan AB; Hong GS; Arni Prabhakaran SK
    Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.